Artículos por temáticas

Opsoclonus-myoclonus syndrome attributable to hepatitis C infection.

Ertekin V, Tan H.

Pediatr Neurol. 2010 Jun;42(6):441-2. doi: 10.1016/j.pediatrneurol.2010.02.009.

Sildenafil induced choreoathetosis in men with Parkinson's disease.

Perkovic O, Vitezic D, Rudez J, Vitezic M, Kovacevic M, Mrsic-Pelcic J, Ljubicic D, Jurjevic A.

Int J Clin Pharmacol Ther. 2010 Jan;48(1):76-8.

Cancer risk in association with Parkinson disease: a population-based study.

Becker C, Brobert GP, Johansson S, Jick SS, Meier CR.

Parkinsonism Relat Disord. 2010 Mar;16(3):186-90. doi: 10.1016/j.parkreldis.2009.11.005.

Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3.

Menzies FM, Huebener J, Renna M, Bonin M, Riess O, Rubinsztein DC.

Brain. 2010 Jan;133(Pt 1):93-104. doi: 10.1093/brain/awp292.

Using point process models to compare neural spiking activity in the subthalamic nucleus of Parkinson's patients and a healthy primate.

Sarma SV, Eden UT, Cheng ML, Williams ZM, Hu R, Eskandar E, Brown EN.

IEEE Trans Biomed Eng. 2010 Jun;57(6):1297-305. doi: 10.1109/TBME.2009.2039213.

Global microRNA expression profiling of Caenorhabditis elegans Parkinson's disease models.

Asikainen S, Rudgalvyte M, Heikkinen L, Louhiranta K, Lakso M, Wong G, Nass R.

J Mol Neurosci. 2010 May;41(1):210-8. doi: 10.1007/s12031-009-9325-1.

GM1 ganglioside in Parkinson's disease: Results of a five year open study.

Schneider JS, Sendek S, Daskalakis C, Cambi F.

J Neurol Sci. 2010 May 15;292(1-2):45-51. doi: 10.1016/j.jns.2010.02.009.

[Quantitative measurement of axial rigidity, functional status and health-related quality of life in patients with Parkinson's disease].

Cano de la Cuerda R, Vela L, Miangolarra-Page JC, Macías-Macías Y, Muñoz-Hellín E.

Rev Neurol. 2010 Aug 16;51(4):193-200. Spanish.

Multicenter study report: electrophysiological monitoring procedures for subthalamic deep brain stimulation surgery in Parkinson's disease.

Marceglia S, Mrakic-Sposta S, Tommasi G, Bartolomei L, Foresti C, Valzania F, Galati S, Stefani A, Tamma F, Priori A; DBS Study Group of The Italian Neurological Society..

Neurol Sci. 2010 Aug;31(4):449-57. doi: 10.1007/s10072-010-0254-0.

Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis.

Gagne JJ, Power MC.

Neurology. 2010 Mar 23;74(12):995-1002. doi: 10.1212/WNL.0b013e3181d5a4a3. Review.

Lateralized response of oxytocinase activity in the medial prefrontal cortex of a unilateral rat model of Parkinson's disease.

Banegas I, Prieto I, Vives F, Alba F, de Gasparo M, Duran R, Segarra AB, Ramírez M.

Behav Brain Res. 2010 Dec 1;213(2):328-31. doi: 10.1016/j.bbr.2010.05.030.

Invited commentary: why do orofacial movement disorders cause me to brux?

Goldstein G.

Int J Prosthodont. 2010 May-Jun;23(3):221-2. No abstract available.

Parkinson disease: sialorrhea and Parkinson disease--novel treatment approaches.

Troche MS, Fernandez HH.

Nat Rev Neurol. 2010 Aug;6(8):423-4. doi: 10.1038/nrneurol.2010.107.

Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease.

Okun MS, Lang A, Jankovic J.

Mov Disord. 2010 May 15;25(7):961-2; author reply 962-3. doi: 10.1002/mds.23021. No abstract available.

A recommended scale for cognitive screening in clinical trials of Parkinson's disease.

Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Tröster AI, Uc EY; Parkinson Study Group Cognitive/Psychiatric Work

Mov Disord. 2010 Nov 15;25(15):2501-7. doi: 10.1002/mds.23362.